Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001241330 | SCV001414343 | uncertain significance | not provided | 2021-12-23 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 696 of the ELP1 protein (p.Arg696Gln). This variant is present in population databases (rs137853022, gnomAD 0.07%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with ELP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 966606). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant disrupts the p.Arg696 amino acid residue in ELP1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11179008). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV001241330 | SCV002545707 | uncertain significance | not provided | 2022-04-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004034676 | SCV002754622 | uncertain significance | not specified | 2020-03-24 | criteria provided, single submitter | clinical testing | The p.R696Q variant (also known as c.2087G>A), located in coding exon 18 of the IKBKAP gene, results from a G to A substitution at nucleotide position 2087. The arginine at codon 696 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002491803 | SCV002793545 | uncertain significance | Medulloblastoma; Familial dysautonomia | 2022-02-04 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001835098 | SCV002082095 | uncertain significance | Familial dysautonomia | 2020-05-13 | no assertion criteria provided | clinical testing |